A Phase 2 interventional study of ACR16 and Placebo in Huntington Disease, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 28 sites in 2 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 17th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2008, is one of 28 in phase 2, and was the 26th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 6 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a placebo capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), placebo capsule will be taken twice daily (BID) as 2 separate doses.
Other: Placebo
Participants will receive ACR16 10 milligrams (mg) capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 10 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 20 mg).
Drug: ACR16
Participants will receive ACR16 22.5 mg capsule orally once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 22.5 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 45 mg).
Drug: ACR16
Participants will receive ACR16 45 mg capsule once daily for the first 4 weeks. After 4 weeks (Weeks 5 to 12), ACR16 45 mg capsule will be taken twice daily (BID) as 2 separate doses (total dose: 90 mg).
Drug: ACR16
ACR16 will be administered per dose and schedule specified in the arm description.
Also known as: pridopidine
Placebo matching to ACR16 will be administered per schedule specified in the arm description.
Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12
The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS included dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items were rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranged from 0 to 52, with higher scores indicating more severe motor impairment. The last observation carried forward (LOCF) method was used to generate an mMS score for each participant for Week 12 assessment.
Time frame: Baseline, Week 12
Change From Baseline in Total Motor Score (TMS)
The UHDRS Motor Assessment comprises 31 responses from the 15 items, where each response is rated on a 5-point scale from 0 (normal) to 4 (maximally abnormal). The Total Motor Score (TMS) is the sum of all the 31 responses with higher scores indicating more severe motor impairment than lower scores.
Time frame: Basline, Week 12
Number of Participants in Each of the Ratings of the Clinical Global Impression of Change (CGI-C) Scale
The CGI-C was rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.
Time frame: Week 12
Change From Baseline in Stroop Word Reading Test
The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.
Time frame: Baseline, Week 12
Change From Baseline in Total UHDRS Behavioral Assessment Score
The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.
Time frame: Baseline, Week 12
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score
HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0-42. Lower change from baseline scores indicate improvement.
Time frame: Baseline, Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
Time frame: Baseline up to Week 14
| Milestone | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Started | 58 | 56 | 55 | 58 |
| Received at least 1 dose of study drug | 58 | 56 | 55 | 58 |
| Full analysis set | 58 | 55 | 55 | 58 |
| Completed | 55 | 51 | 52 | 55 |
| Not completed | 3 | 5 | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 2 |
| Withdrew: Investigator decision | 0 | 0 | 1 | 0 |
| Withdrew: Did not tolerate study drug | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 1 | 1 | 0 | 0 |
The mMS is a subscale of the UHDRS total motor score and comprises 13 responses from the 10 items, 4-10 and 13-15, from the UHDRS motor assessment. The items for mMS included dysarthria, tongue protrusion, finger taps (right and left), pronate/supinate hands (right and left), luria - first-hand-palm sequencing, arms rigidity (right and left), body bradykinesia, gait, tandem walking, and retropulsion pull test. Each of these items were rated on a scale of 0 (normal) to 4 (marked impairment). Total score ranged from 0 to 52, with higher scores indicating more severe motor impairment. The last observation carried forward (LOCF) method was used to generate an mMS score for each participant for Week 12 assessment.
| units on a scale | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12 | -1.40 ± 3.72 | -1.30 ± 3.33 | -2.49 ± 3.37 | -2.32 ± 3.72 |
The UHDRS Motor Assessment comprises 31 responses from the 15 items, where each response is rated on a 5-point scale from 0 (normal) to 4 (maximally abnormal). The Total Motor Score (TMS) is the sum of all the 31 responses with higher scores indicating more severe motor impairment than lower scores.
| Units on a scale | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Change From Baseline in Total Motor Score (TMS) | -2.09 ± 8.31 | -1.92 ± 6.07 | -3.30 ± 6.91 | -4.61 ± 7.21 |
The CGI-C was rated by the investigator on a 7-point scale as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; and 7 = Very much worse.
| Participants | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Not assessed | 0 | 1 | 1 | 2 |
| Very much improved | 0 | 1 | 2 | 4 |
| Much improved | 8 | 3 | 8 | 4 |
| Minimally improved | 20 | 14 | 17 | 21 |
| No change | 24 | 31 | 22 | 25 |
| Minimally worse | 4 | 4 | 5 | 1 |
| Much worse | 1 | 1 | 0 | 1 |
| Very much worse | 0 | 0 | 0 | 0 |
The Stroop test measures the ability to concentrate and ward off distractions. The test consists of three items: (i) colour naming; (ii) word reading; (iii) interference. The word reading test requires participants to read colour words written in black and each response is scored as the number of correct answers made in 45 seconds. Higher scores indicate less severe disease, and an increase in score represents an improvement.
| correct responses | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Change From Baseline in Stroop Word Reading Test | 2.5 ± 13.0 | 3.7 ± 10.6 | -0.0 ± 12.7 | 2.8 ± 10.5 |
The total behavioral assessment score is the sum of the 11 products (depressed mood, apathy, low self-esteem/guilt, compulsive behavior, anxiety, irritable behavior, perseverative/obsessive thinking, disruptive/aggressive behavior, suicidal thoughts, delusions, and hallucinations) of frequency and severity symptom scores and excluded the 3 yes/no questions relating to confusion, dementia, and depression. Frequency is rated on a scale of 0 (never or almost never) to 4 (very frequently, most of the time). Severity is rated on a scale of 0 (no evidence) to 4 (severe). Total behavior score ranges from 0 (no impairment) to 88 (severe impairment), with higher scores indicating greater behavioral impairments.
| Units on a scale | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Change From Baseline in Total UHDRS Behavioral Assessment Score | -3.56 ± 8.51 | -3.24 ± 11.24 | -3.45 ± 10.10 | -6.19 ± 10.17 |
HADS is a self-administered instrument reliable for detecting states of depression and anxiety. It includes 2 subscales: Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale is comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score ranges from 0 to 21 for each subscale where higher scores indicate greater severity of anxiety and depression symptoms. The total HADS score was a composite score summed of all 14 items for a total range of 0-42. Lower change from baseline scores indicate improvement.
| Units on a scale | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score | -1.04 ± 3.67 | -1.24 ± 4.57 | -0.95 ± 4.68 | -2.10 ± 5.68 |
An adverse event (AE) was defined as any change from the participant's baseline (pre-treatment) condition, other than improvement, that did not necessarily have causal relationship with the study drug. TEAEs were defined as adverse events that began after ACR16/placebo administration. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Participants | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 33 | 30 | 25 | 40 |
Collected over Baseline up to Week 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/58 (1.7%) | 22/58 (37.9%) |
| ACR16 10mg BID | — | 0/56 (0%) | 18/56 (32.1%) |
| ACR16 22.5 mg BID | — | 2/55 (3.6%) | 16/55 (29.1%) |
| ACR16 45 mg BID | — | 3/58 (5.2%) | 30/58 (51.7%) |
| Event | Placebo | ACR16 10mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| ConvulsionNervous system disorders | 0/58 | 0/56 | 1/55 | 0/58 |
| DepressionPsychiatric disorders | 0/58 | 0/56 | 1/55 | 0/58 |
| Suicidal ideationPsychiatric disorders | 0/58 | 0/56 | 1/55 | 0/58 |
| Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/58 | 0/56 | 0/55 | 0/58 |
| Adjustment disorderPsychiatric disorders | 0/58 | 0/56 | 0/55 | 1/58 |
| Bipolar disorderPsychiatric disorders | 0/58 | 0/56 | 0/55 | 1/58 |
| Testicular torsionReproductive system and breast disorders | 0/58 | 0/56 | 0/55 | 1/58 |
| Event | Placebo | ACR16 10mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID |
|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 7/58 | 9/56 | 8/55 | 8/58 |
| NauseaGastrointestinal disorders | 4/58 | 2/56 | 1/55 | 5/58 |
| FatigueGeneral disorders | 5/58 | 1/56 | 2/55 | 2/58 |
| DiarrhoeaGastrointestinal disorders | 3/58 | 3/56 | 4/55 | 2/58 |
| Urinary tract infectionInfections and infestations | 1/58 | 1/56 | 0/55 | 4/58 |
| ExcoriationInjury, poisoning and procedural complications | 4/58 | 1/56 | 2/55 | 1/58 |
| DizzinessNervous system disorders | 0/58 | 0/56 | 0/55 | 4/58 |
| DepressionPsychiatric disorders | 4/58 | 2/56 | 2/55 | 2/58 |
| HeadacheNervous system disorders | 3/58 | 3/56 | 3/55 | 3/58 |
| Huntington's choreaNervous system disorders | 2/58 | 3/56 | 2/55 | 3/58 |
The full analysis set was defined as all randomized participants who received at least 1 dose of study drug and had undergone at least 1 clinical assessment post randomization.
| Age, Continuous(years) | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 49.9 ± 10.6 | 54.0 ± 10.8 | 50.0 ± 10.5 | 50.3 ± 9.7 | 51.0 ± 10.5 |
| Sex: Female, Male(Participants) | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID | Total |
|---|---|---|---|---|---|
| Female | 33 | 32 | 27 | 28 | 120 |
| Male | 25 | 23 | 28 | 30 | 106 |
| Race/Ethnicity, Customized(Participants) | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID | Total |
|---|---|---|---|---|---|
| Hispanic/Latino | 0 | 2 | 0 | 2 | 4 |
| American Indian or Alaskan Native | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 2 | 1 | 6 |
| White | 56 | 52 | 52 | 54 | 214 |
| More than 1 Race | 0 | 0 | 1 | 1 | 2 |
| Unified Huntington's Disease Rating Scale (UHDRS) Modified Motor Score (mMS)(units on a scale) | Placebo | ACR16 10 mg BID | ACR16 22.5 mg BID | ACR16 45 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 17.19 ± 6.49 | 16.96 ± 6.18 | 14.18 ± 5.03 | 16.22 ± 6.39 | 16.15 ± 6.13 |
Ran from Oct 2008 to primary completion in Jul 2010, 21 months.
Results were first posted in Aug 2023, 13 years 1 month after primary completion. A results delay was requested in Feb 2013.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Teva Branded Pharmaceutical Products R&D, Inc. →